2024
Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy
Nakashima J, Khatri V, Cruz-Chamorro R, Zhou J, Patra P, Gaballa S, Khimani F, Mirza S, Shah B, Saeed H, Chavez J, Locke F, Nishihori T, Liu H, Dong N, Lazaryan A, Robinson T, Freeman C, Jain M, Figura N. Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e646-e647. DOI: 10.1016/j.ijrobp.2024.07.1421.Peer-Reviewed Original ResearchLarge B-cell lymphomaSecondary CNS lymphomaB-cell lymphomaCNS failureCNS recurrenceCNS diseaseCNS lymphomaCAR-TOverall survivalBridging therapyCNS diagnosisRelapsed/refractory large B-cell lymphomaChimeric antigen receptor T cellsCAR-T cell trialsPattern of failure analysisCAR-T cell therapyMedian age of patientsClinical outcomes of patientsCNS-only progressionSystemic disease recurrenceT-cell therapyCAR-T therapyCytokine-release syndromePatterns of recurrenceKaplan-Meier method
2021
In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Sim A, Figura N, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s131. DOI: 10.1016/j.ijrobp.2021.07.297.Peer-Reviewed Original ResearchMetabolic tumor volumeRefractory large B-cell lymphomaCAR T-cell infusionLarge B-cell lymphomaT-cell infusionT-cell therapyB-cell lymphomaTreatment failureChimeric antigen receptor T-cell therapyField local control rateCAR T-cell therapyBaseline PET/CTLocal failureCAR-T infusionExperience disease progressionLower RT dosesDisease-free survivalLocal control rateMajority of patientsAdequate local controlCAR-T therapyPatterns of failurePET/CTMATERIAL/METHODSCommon regimens